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Summary In breast cancer, oestrogen regulated genes, such as pS2, may be expressed in well differentiated
tumours with a good prognosis. We have examined pS2 mRNA expression in 78 primary, untreated breast
cancers and related pS2 expression to disease behaviour and known prognostic factors. pS2 mRNA expression
was detected in 25/78 (32%) of cancers and was significantly associated with a moderate/high oestrogen
receptor content (P = 0.045, Chi Square test). pS2 mRNA expression was associated with freedom from
disease at median 31 months clinical and radiological follow-up (P = 0.015, Fisher's exact test, odds ratio
8.6).
Using multiple logistic regression analysis of six potential prognostic factors only pathological axillary node
status (P<0.01) and pS2 mRNA expression (P<0.05) provided independent prognostic information. Further-
more, pS2 was associated with a good prognosis in the axillary node positive patients where only 1/13 (8%)
with pS2 mRNA expression compared with 13/29 (45%) without detectable expression had recurrence of their
disease. These data provides strong support for pS2 as a useful independent prognostic factor in primary
breast cancer.
It is almost 100 years since the oestrogen-dependence of
breast cancer was first demonstrated (Beatson, 1896). How-
ever, since the oestrogen receptor content of a breast tumour
is an imperfect predictor of response to endocrine therapy
(Leake, 1987), with defects in the regulation of oestrogen
receptor function perhaps explaining why some patients fail
to respond (Schwartz et al., 1991), attention has turned to
oestrogen-regulated genes in an attempt to define more
accurately the role of oestrogen in individual tumours. One
of these genes, variously known as pS2 (Masiakowski et al.,
1982), pNR2 (Westley & May, 1991), Md2 (Skilton et al.,
1989) and BCE1 (Prud, homme et al., 1984) has received
particular attention.
Located on chromosome 21q (Moison et al., 1988), the
pS2 gene comprises 3 exons of 125, 153 and 212 base-pairs
interrupted by 2 introns of 3.1 kb (intron A) and 0.77 kb
(intron B) (Jakowlew et al., 1984; Jeltsh et al., 1988; Stack et
al., 1988; Mori et al., 1990). There are two start sites for
transcription, one of which predominates (Mori et al., 1990)
to generate a 600-base mRNA (Masiakowski et al., 1982;
Stack et al., 1988) that encodes an 84-amino-acid, precursor
protein of 9.14 kda (Stack et al., 1988), which is cleaved to a
7 kda 60-amino-acid polypeptide (Stack et al., 1988, Mori et
al., 1990) and is secreted from the cell (Brown et al., 1984).
This cysteine-rich protein (Rio et al., 1987), capable of form-
ing 3 disulphide bonds (Stack et al., 1988), has structural
similarities to Insulin Like Growth Factor I and Insulin Like
Growth Factor II (Rio et al., 1987; Stack et al., 1988) and
porcine pancreatic spasmolytic polypeptide (Rio et al.,
1988).
Expression of the mRNA for pS2 increases in response to
an oestrogenic stimulus (Masiakowski et al., 1982; Brown et
al., 1984; Stack et al., 1988) and coincides with the
appearance of highly associated oestrogen to oestrogen-
receptor complexes in the nucleus (Brown et al., 1984). Oest-
rogenic stimulation of pS2 can be antagonised by tamoxifen
(May & Westley, 1987) although tamoxifen may itself act as
a weak agonist for pS2 expression (Johnston et al., 1989).
While pS2 expression is not influenced by progestins,
glucocorticoids or androgens (Brown et al., 1984), pS2 can be
induced by EGF and by agents elevating cAMP through
indirect mechanisms (requiring protein synthesis) in addition
to the primary transcriptional effects of oestrogenic stimula-
tion (Cavailles et al., 1989).
However, the function of pS2 and its biological
significance remain uncertain. pS2 is certainly secreted from
oestrogen-dependent cell lines (Brown et al., 1984) and does
not appear to stimulate DNA synthesis directly (Kida et al.,
1989) but may act in an autocrine or paracrine manner. In
view of its oestrogen-dependence, pS2 expression may reflect
tumour differentiation and therefore may be an index of
prognosis.
The aims of this study were to examine pS2 mRNA exp-
ression in primary breast cancer and to determine whether
pS2 could be related to patient prognosis and to other fac-
tors of established prognostic significance.
Materials and methods
Patients
Seventy eight female patients with primary breast cancer
attending the Breast Unit, University Department of Surgery,
Edinburgh were studied. At the time of diagnosis the patients
(age range 34-84) had received no anticancer therapy and
had no evidence of distant metastatic disease. Twenty-six of
the women were premenopausal and the remaining 52 post-
menopausal. The primary tumour was less than 5 cm (T2) in
44 patients, and over 5 cm (T3) or locally advanced (T4) in 34
patients. There was histological evidence of nodal metastasis
in 42 of the 78 patients.
Patient follow-up was conducted at 3 to 4 month intervals
for the first 24 months and thereafter at 6 month intervals. In
addition to clinical examination, annual chest radiography
and, where appropriate, mammography, were performed. On
disease relapse, patients were restaged to establish the extent
of disease and the sites of recurrence.
Tissues
Tumour tissue was snap frozen in liquid nitrogen at the time
of surgery and stored at - 70°C. Adjacent tissue was submit-
ted for the determination of oestrogen receptor content and
for histopathological confirmation of malignancy (although
this did not include pathological grade).
Normal breast tissue from ten patients who underwent
reduction mammoplasty and who had no personal or family
history of breast cancer were also obtained fresh and snap
frozen.
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The breast cancer cell lines MCF-7 (Soule et al., 1973),
MDA-MB-231 (Cailleau et al., 1974) and T-47D (Keydar et
al., 1979) were grown in vitro, harvested in the logarithmic
phase of growth and total RNA was extracted for com-
parison with that from the tumours.
Ribonucleic acid extraction
From frozen tumour, total ribonucleic acid (RNA) was ex-
tracted using a modification of the method of Auffrey &
Rougeon (1980). Briefly, pulverised frozen tumour or cul-
tured cells washed in phosphate-buffered saline was disrupted
in 3 M lithium chloride/6 M urea (2 ml per 100 mg tissue) and
precipitated at 4°C overnight. The DNA was sheared using a
Soniprep 150 ultrasonic disintegrator (MSE Scientific
Instruments, Crawley, UK) with an ice-jacket, the RNA was
recovered by centrifugation at 12,000 r.p.m. and the pellet
was taken up in 6 ml of 10mM Tris buffer pH 7.0/0.1%
sodium dodecyl sulphate (SDS). Following digestion with
proteinase K, residual protein was extracted using phenol
equilibrated with tris buffer (0.1 M, pH 7) and
chloroform:isoamylalcohol (24:1).
Following ethanol precipitation of the aqueous phase at
- 20°C, the RNA was recovered by centrifugation and dis-
solved in autoclaved distilled water treated with diethyl-
pyrocarbonate (DEPC, Sigma, USA) and stored in aliquots
at - 70C. The quantity and purity of the RNA was assessed
by spectrophotometry at 260 nm and 240 nm.
Electrophoresis and transfer ofRNA
Twenty micrograms of total RNA was denatured with for-
mamide and formaldehyde at 55°C for 20 min; 2jl loading
buffer (50% glycerol, 1 mM EDTA 0.4% bromophenol blue,
0.4% xylene cyanol) and I 1l of 10fgfl' ethidium bromide
were added to each sample. The denatured RNA species were
separated by electrophoresis on a 1.1% agarose gel contain-
ing 0.66 M formaldehyde, submerged beneath MOPS buffer
(Morpholinopropanesulphonic acid 0.2M, pH 7.0, 50 mM
sodium acetate pH 7.0, 5 mM EDTA).
The gel was washed in two changes of 10 x standard
saline citrate solution, photographed under a UV transil-
luminator and the RNA was transferred to a nylon filter
(Hybond-N, Amersham, UK) by capillary action using
10 x SSC over 8 h. The filter was rinsed in 2 x SSC, air-dried
and the RNA was covalently fixed to the membrane using a
UV transilluminator. The filter and remaining gel were
photographed to check for adequate transfer of the RNA.
Probe hybridisation
To detect the pS2 mRNA, a cDNA probe (Masiakowski et
al., 1982) was used. Filters were prehybridised in 7% SDS.
0.5 M disodium hydrogen phosphate (pH 7.2) and 1 mM
EDTA pH 7.0 for 30 min at 65°C. To this was added 32p
cytidine triphosphate (CTP)-labelled cDNA probe, with
specific activity to 1 x I07c.p.m. ml' achieved using a ran-
domprime DNA-labelling system (Boehringer Mannheim,
West Germany); 32P-CTP-incorporated probe was separated
from unincorporated radionucleotide using a Sephadex col-
umn (Nick column, Pharmacia, UK) and denatured before
addition to the hybridisation solution.
Following hybridisation for 24 h, filters were washed to
remove non-specifically attached probe in two changes of
0.1% SDS, 10 mM disodium hydrogen phosphate washing-
buffer at 65°C with agitation. Filters were exposed to
preflashed Kodak XAR film at - 70°C for 3 days. The filter
was stripped of pS2 using 0.1% SDS at 80°C for 30 min and
reprobed with the internal control (the 1.4 kb Pst insert
cDNA for actin mRNA; Minty et al., 1981), to quantify the
amount of intact mRNA present.
The extent of hybridisation of radiolabelled probe to the
mRNA species was determined from laser densitometry and
expressed with respect to hybridisation of the actin probe.
The size of the pS2 mRNA species was calculated from the
position of ribosomal RNA markers.
Steroid hormone receptors
The oestrogen receptor content was measured using the
Enzyme Immunosorbent Assay (EIA: kit from Abbot
Laboratories, North Chicago, Illinois: Hawkins et al., 1987)
and expressed in fmol mg total protein'. Oestrogen receptor
protein concentrations of 20 fmol mgprotein-' or greater
were considered to be clinically significant (Anderson et al.,
1989).
The progesterone receptor content of these tumours was
not assayed. Progesterone receptor, unlike oestrogen receptor
content, is not used in our clinical practice to influence the
choice of therapy.
Results
Total RNA was extracted and northern blots successfully
probed for pS2 mRNA and alpha actin expression in 78
untreated primary breast cancers (Figure 1). pS2 mRNA
expression was detected in 25/78 (32%) of the cancers, 6/10
normal breast tissues, and in the cell lines MCF 7 and T47D
but not in the cell line MDA MB 231.
Expression of mRNA for pS2 was compared with oest-
rogen receptor protein expression in the same tumours (Table
I). Forty-five of the 78 tumours (58%) were considered to
have a moderate or rich oestrogen receptor content
>20 fmol mg protein-') and the remaining 33 were oest-
rogen receptor poor/negative. pS2 mRNA expression was
significantly associated with moderate/high oestrogen recep-
tor content (P = 0.045, chi square test); however, there were
six tumours (18%) with pS2 mRNA expression of the 33
which were oestrogen receptor poor.
pS2 mRNA expression in the primary tumour was com-
pared with disease behaviour at a minimum follow-up of 24
months (median 31 months; range 24 months to 37 months),
(Table II). Amongst the 25 patients with pS2 mRNA expres-
sion in the primary tumour, only one patient had disease
recurrence (4%). Patients with tumour pS2 mRNA expres-
sion were very likely to be disease-free at 24 months
(P = 0.015, Fisher's exact test; odds ratio 8.6). The tumour
oestrogen receptor protein content was not related to disease
behaviour within the follow-up period studied (Table II).
However, the presence of axillary nodal metastases, assessed
on pathological examination at the time of surgery, cor-
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Figure 1 Expression of the mRNA for pS2 in breast cancer.
Northern blots of the RNA extracted from breast tumours,
breast cancer cell lines and normal breast tissue showing 600 base
pS2 mRNA (upper panel) and 1.8 kb actin mRNA (internal
control lower panel). pS2 expression is illustrated for one of two
breast tumours, two of the three cell lines and at a low level in
the normal breast tissue.PS2 IN PROGNOSIS OF BREAST CANCER 95
Table I Expression of the mRNA for pS2 and tumour oestrogen
receptor content in 78 human breast cancers
Oestrogen receptor protein
(fmolmg protein-')
>20 <20
Detected 19 6
pS2 mRNA
expression
Nil 26 27
(Chi square test P = 0.045; n = 78).
Table II Expression of pS2 mRNA tumour oestrogen receptor
content, axillary node involvement and disease recurrence in 78
patients with primary breast cancer
pS2 mRNA Oestrogen Node
expression receptor involvement
0 + <20 >20 0 +
Disease recurrence 14 1 7 8 1 14
Disease-free 39 24 26 37 35 28
Fisher's exact test P = 0.015 P = 0.46 P <0.01
(n = 78)
Odds ratio 8.6 1.24 17.5
(confidence intervals) (1.14, 379) (0.33, 4.48) (2.3, 760)
related most significantly with disease recurrence (P<0.01
Fisher's exact test; odds ratio 17.5), (Table II).
Multiple logistic regression analysis of six potential prog-
nostic factors (pathological node status, pS2 mRNA expres-
sion, tumour oestrogen receptor content, pathological
tumour size, clinical stage (TNM system) and menopausal
status demonstrated that within the follow-up period studied,
only pathological axillary node status at the time of surgery
(P<0.01) and pS2 mRNA expression (P<0.05) were signifi-
cantly associated with behaviour of the disease and provided
independent prognostic information. Indeed, when these two
parameters are combined (Table III) it is clear that pS2
expression delineates subgroups of patients with an excellent
prognosis when added to node status. This is most marked
amongst the axillary node-positive group where only 8%
(1/13) with pS2 mRNA expression compared with 45% (13/29)
without detectable expression had recurrence of their
disease.
Discussion
We have detected pS2 mRNA in primary breast cancers,
normal breast tissue and two breast cancer cell lines and
related pS2 expression to other useful clinical parameters and
to disease behaviour.
pS2 mRNA was detected in 32% of breast cancers, less
commonly than in most other studies ofpS2 mRNA (43% to
58%; Rio et al., 1987; Stack et al., 1988; Skilton et al., 1989;
Henry et al., 1990; Zaretsky et al., 1990; Hahnel et al., 1991)
but within the range for pS2 protein detection (27% to 68%,
Foekens et al., 1990; Henry et al., 1991; Schwartz et al.,
1991).
Although pS2 expression was initially considered to be
breast cancer-specific (Stack et al., 1988), most recent studies
have demonstrated pS2 expression in normal breast (Predine
Table III Expression of pS2 mRNA, axillary node status and
recurrence in 78 patients with primary breast cancer
Axillary node pS2 mRNA Proportion of group
metastasis expression with recurrence (%)
Negative + 0/12 (0%)
Negative - 1/24 (4%)
Positive + 1/13 (8%)
Positive - 13/29 (45%)
et al., 1992), uninvolved breast tissue from breast cancer
patients (Hahnel et al., 1991), benign breast tissues (Skilton
et al., 1989; Zaretsky et al., 1990; Predine et al., 1992) and
benign and malignant tissues from the thyroid, stomach,
colon, bladder and ovary (Zaretsky et al., 1990). In keeping
with this, pS2 expression was noted in 6/10 of our reduction
mammoplasty specimens. Not surprisingly, pS2 expression
was detected at high levels in the MCF7 and T47D
oestrogen-dependent breast cancer cell lines, but not in the
MDA MB 231 cell line which does not express oestrogen
receptor protein.
pS2 expression was significantly associated with oestrogen
receptor protein expression in the 78 tumours examined. This
confirms previous studies in which the two have been cor-
related (Rio et al., 1988; Skilton et al., 1989; Stack et al.,
1988; Schwartz et al., 1991; Henry et al., 1991; Predine et al.,
1992). In this series there were tumours with detectable pS2
mRNA which were oestrogen receptor poor (Rio et al., 1988;
Skilton et al., 1989) and tumours containing oestrogen recep-
tor protein at the clinically significant level >20fmol mg
protein-' level (Anderson et al., 1989) but without detectable
pS2 mRNA. However, pS2 mRNA may be detectable only
when oestrogen receptor mRNA is also expressed (Henry et
al., 1990; Westley & May, 1991), although we did not
examine oestrogen receptor mRNA. It may be that the
tumours producing pS2 mRNA but not oestrogen receptor
protein were failing to translate the mRNA for the oestrogen
receptor into functional protein or that pS2 mRNA expres-
sion may have been stimulated by other, unrelated, factors
(Cavailles et al., 1989).
In this study we confirmed that there are no statistically
significant associations between pS2 mRNA expression and
tumour size (Foekens et al., 1990; Schwartz et al., 1991),
node status (Foekens et al., 1990; Schwartz et al., 1991) or
tumour grade (Foekens et al., 1990) in contrast to the weak
associations noted by one other group (Henry et al., 1991).
While there may be, as here, no clear association between
menopausal status and pS2 expression (Henry et al., 1990) it
should be noted that others have found higher pS2 expres-
sion in premenopausal women (Foekens et al., 1990; Henry
et al., 1991; Predine et al., 1992).
The remarkable association between pS2 mRNA expres-
sion in the primary tumour and freedom from recurrence of
disease at a median of 31 months careful clinical and
radiological follow-up suggests that pS2 expression is a good
prognostic factor and confirms the converse that absence of
pS2 in the primary tumour corresponds with a short disease-
free interval and poorer overall survival (May et al., 1988;
Foekens et al., 1990; Schwartz et al., 1991; Predine et al.,
1992). This could be because pS2 expression may reflect a
genuinely oestrogen-sensitive tumour (Schwartz et al., 1991).
In keeping with this is the experimental (Johnson et al., 1989)
and clinical evidence that pS2 expression predicts a subse-
quent response to hormonal manipulation initially (Skilton et
al., 1989; Westley & May, 1991; Schwartz et al., 1991; Henry
et al., 1990; Ramm et al., 1988; Henry et al., 1988) and on
relapse (Henry et al., 1991; Schwartz et al., 1991). Since only
50%-65% of oestrogen receptor-positive tumours actually
respond to anti-oestrogen therapy (Stack et al., 1988), we
concur that pS2 may be more useful than oestrogen receptor
measurement in predicting response to endocrine therapy
(Predine et al., 1992).
Ofparticular note in this study was the prognostic value of
pS2 measurements for patients who had axillary nodal metas-
tases at diagnosis. Clearly, the presence of pS2 mRNA ex-
pression, like pS2 cytosol protein measurement (Foekens et
at., 1990) defines a group of node-positive patients who at
medium-term follow-up have a comparatively good prog-
nosis. Examining tumours for pS2 expression therefore pro-
vides the basis for subclassifying node-positive patients into
good or poor prognostic groups. Combined with the pub-
lished evidence that pS2 is a marker for hormone-dependent
breast cancer, our findings suggest that pS2 is an important
prognostic and predictive factor. In particular, those patients
with axillary node metastases but no tumour pS2 expression96 A.M. THOMPSON et al.
are at high risk of early disease recurrence. Unfortunately,
hormonal manipulation in these patients is unlikely to be
beneficial and so it is to this group that chemotherapy and
new adjuvant therapies should be directed.
We thank P. Chambon for permission to use the pS2 probe, B.
Cohen for helpful comments and N. Davidson and colleagues for the
Figure.
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